Repligen (NASDAQ:RGEN) PT Lowered to $185.00 at UBS Group

Repligen (NASDAQ:RGEN) had its target price decreased by UBS Group from $205.00 to $185.00 in a research note published on Wednesday, Benzinga reports. UBS Group currently has a buy rating on the biotechnology company’s stock.

RGEN has been the topic of a number of other research reports. Stephens restated an overweight rating and set a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th. Guggenheim assumed coverage on Repligen in a research report on Tuesday, June 18th. They issued a neutral rating for the company. Royal Bank of Canada reiterated an outperform rating and set a $190.00 target price on shares of Repligen in a research report on Wednesday. JPMorgan Chase & Co. lowered their price target on Repligen from $230.00 to $200.00 and set an overweight rating for the company in a report on Thursday, May 2nd. Finally, Deutsche Bank Aktiengesellschaft raised shares of Repligen from a hold rating to a buy rating and decreased their target price for the stock from $180.00 to $155.00 in a research report on Wednesday, June 26th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Repligen presently has an average rating of Moderate Buy and an average price target of $189.57.

Repligen Stock Performance

Shares of RGEN opened at $161.67 on Wednesday. The company has a quick ratio of 5.24, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. Repligen has a 52-week low of $110.45 and a 52-week high of $211.13. The company has a 50-day simple moving average of $134.92 and a 200-day simple moving average of $166.00. The company has a market capitalization of $9.06 billion, a PE ratio of 646.71, a P/E/G ratio of 5.98 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The business had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter last year, the business posted $0.53 earnings per share. Equities research analysts predict that Repligen will post 1.44 earnings per share for the current fiscal year.

Insider Activity at Repligen

In other Repligen news, CEO Anthony Hunt bought 2,000 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were acquired at an average cost of $124.08 per share, for a total transaction of $248,160.00. Following the acquisition, the chief executive officer now directly owns 165,177 shares of the company’s stock, valued at $20,495,162.16. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Anthony Hunt acquired 2,000 shares of Repligen stock in a transaction on Friday, June 14th. The stock was bought at an average cost of $124.08 per share, with a total value of $248,160.00. Following the completion of the purchase, the chief executive officer now owns 165,177 shares of the company’s stock, valued at $20,495,162.16. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Martin D. Madaus acquired 1,615 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was purchased at an average cost of $124.94 per share, with a total value of $201,778.10. Following the purchase, the director now directly owns 4,613 shares in the company, valued at approximately $576,348.22. The disclosure for this purchase can be found here. Company insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Institutional investors have recently made changes to their positions in the company. YHB Investment Advisors Inc. bought a new position in shares of Repligen during the 1st quarter valued at $26,000. Lazard Asset Management LLC raised its holdings in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 136 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its position in shares of Repligen by 152.1% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after buying an additional 146 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of Repligen during the 2nd quarter worth about $33,000. Finally, Principal Securities Inc. acquired a new position in shares of Repligen during the 4th quarter valued at about $48,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.